Trevor A Mori1, Richard J Woodman. 1. School of Medicine and Pharmacology, Royal Perth Hospital Unit, University of Western Australia. Trevor.Mori@uwa.edu.au
Abstract
PURPOSE OF REVIEW: This review details the independent effects of purified eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. We report data from the recent literature and our own controlled clinical trials which compared the independent effects of these fatty acids in individuals at increased risk of cardiovascular disease, namely overweight hyperlipidaemic men and treated-hypertensive, type 2 diabetic men and women. We discuss the biological effects of these fatty acids and the potential mechanisms through which they may affect cardiovascular disease risk factors. RECENT FINDINGS: A cardioprotective effect for omega3 fatty acids is supported by prospective studies demonstrating an inverse association between fish intake and coronary heart disease mortality. Data from secondary prevention trials support a reduction in ventricular fibrillation as a primary mechanism for the decreased incidence of myocardial infarction. Clinical trials and experimental studies have shown that omega3 fatty acids have many other potentially important antiatherogenic and antithrombotic effects. Omega-3 fatty acids lower blood pressure and heart rate, improve dyslipidaemia, reduce inflammation, and improve vascular and platelet function. These favourable effects have until recently been primarily attributed to the omega3 fatty acid eicosapentaenoic acid, which is present in large amounts in fish oil. Controlled studies in humans now demonstrate that docosahexaenoic acid, although often present in lower quantities, has equally important anti-arrhythmic, anti-thrombotic and anti-atherogenic effects. SUMMARY: Available evidence strongly suggests that eicosapentaenoic acid and docosahexaenoic acid have differing haemodynamic and anti-atherogenic properties. The effects of the two fatty acids may also differ depending on the target population.
PURPOSE OF REVIEW: This review details the independent effects of purified eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans. We report data from the recent literature and our own controlled clinical trials which compared the independent effects of these fatty acids in individuals at increased risk of cardiovascular disease, namely overweight hyperlipidaemic men and treated-hypertensive, type 2 diabeticmen and women. We discuss the biological effects of these fatty acids and the potential mechanisms through which they may affect cardiovascular disease risk factors. RECENT FINDINGS: A cardioprotective effect for omega3 fatty acids is supported by prospective studies demonstrating an inverse association between fish intake and coronary heart disease mortality. Data from secondary prevention trials support a reduction in ventricular fibrillation as a primary mechanism for the decreased incidence of myocardial infarction. Clinical trials and experimental studies have shown that omega3 fatty acids have many other potentially important antiatherogenic and antithrombotic effects. Omega-3 fatty acids lower blood pressure and heart rate, improve dyslipidaemia, reduce inflammation, and improve vascular and platelet function. These favourable effects have until recently been primarily attributed to the omega3 fatty acideicosapentaenoic acid, which is present in large amounts in fish oil. Controlled studies in humans now demonstrate that docosahexaenoic acid, although often present in lower quantities, has equally important anti-arrhythmic, anti-thrombotic and anti-atherogenic effects. SUMMARY: Available evidence strongly suggests that eicosapentaenoic acid and docosahexaenoic acid have differing haemodynamic and anti-atherogenic properties. The effects of the two fatty acids may also differ depending on the target population.
Authors: Jason H Y Wu; Rozenn N Lemaitre; Irena B King; Xiaoling Song; Frank M Sacks; Eric B Rimm; Susan R Heckbert; David S Siscovick; Dariush Mozaffarian Journal: Circulation Date: 2012-01-26 Impact factor: 29.690
Authors: Akira Sekikawa; Takashi Kadowaki; Aiman El-Saed; Tomonori Okamura; Kim Sutton-Tyrrell; Yasuyuki Nakamura; Rhobert W Evans; Ken-Ichi Mitsunami; Daniel Edmundowicz; Yoshihiko Nishio; Katsumi Nakata; Aya Kadota; Teruo Otake; Katsuyuki Miura; Jina Choo; Robert D Abbott; Lewis H Kuller; J David Curb; Hirotsugu Ueshima Journal: Stroke Date: 2011-07-14 Impact factor: 7.914
Authors: Linda M Arterburn; Harry A Oken; James P Hoffman; Eileen Bailey-Hall; Gloria Chung; Dror Rom; Jacqueline Hamersley; Deanna McCarthy Journal: Lipids Date: 2007-08-23 Impact factor: 1.880
Authors: Eric Leslie; Vanessa Lopez; Nana A O Anti; Rafael Alvarez; Isaac Kafeero; Donald G Welsh; Monica Romero; Shawn Kaushal; Catherine M Johnson; Remy Bosviel; Ivana Blaženović; Rui Song; Alex Brito; Michael R La Frano; Lubo Zhang; John W Newman; Oliver Fiehn; Sean M Wilson Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-02-24 Impact factor: 5.464
Authors: Ka He; Pengcheng Xun; Theodore M Brasky; Marilie D Gammon; June Stevens; Emily White Journal: Am J Epidemiol Date: 2012-12-05 Impact factor: 4.897
Authors: Zeina Makhoul; Alan R Kristal; Roman Gulati; Bret Luick; Andrea Bersamin; Bert Boyer; Gerald V Mohatt Journal: Am J Clin Nutr Date: 2010-01-20 Impact factor: 7.045
Authors: Montserrat M Diaz Encarnacion; Gina M Warner; Catherine E Gray; Jingfei Cheng; Hesham K H Keryakos; Karl A Nath; Joseph P Grande Journal: Am J Physiol Renal Physiol Date: 2008-04-02